Mesalazine [1g, 2g prolonged-release granules; 1g suppository] for management of ulcerative colitis and ulcerative proctitis
Minor Inclusion | DrugsHTA Council Recommendation (as of 10 October 2023)
As final recommendation, the HTA Council recommends the government financing of mesalazine [1g, 2g prolonged-release granules; 1g suppository] for management of ulcerative colitis and ulcerative proctitis through its inclusion in the Philippine National Formulary (PNF).
Relevant Information
- Status: With Final HTA Council Recommendation and SOH Decision
- Topic Assignment: Internal Assessment
- Policy Question: Should mesalazine [1g, 2g prolonged-release granules; 1g suppository] for management of ulcerative colitis and ulcerative proctitis be funded by the government?
- Secretary of Health Decision: Approved as of 20 October 2023
Evidence and Relevant Documents